ATE530188T1 - Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs - Google Patents

Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs

Info

Publication number
ATE530188T1
ATE530188T1 AT08714327T AT08714327T ATE530188T1 AT E530188 T1 ATE530188 T1 AT E530188T1 AT 08714327 T AT08714327 T AT 08714327T AT 08714327 T AT08714327 T AT 08714327T AT E530188 T1 ATE530188 T1 AT E530188T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cancer agents
delivering anti
pharmaceutically acceptable
Prior art date
Application number
AT08714327T
Other languages
English (en)
Inventor
John Bremner
Philip Clingan
Julie Locke
Original Assignee
Univ Wollongong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wollongong filed Critical Univ Wollongong
Application granted granted Critical
Publication of ATE530188T1 publication Critical patent/ATE530188T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT08714327T 2007-03-02 2008-02-29 Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs ATE530188T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90436307P 2007-03-02 2007-03-02
PCT/AU2008/000276 WO2008106721A1 (en) 2007-03-02 2008-02-29 Compositions and methods for delivery of anti-cancer agents

Publications (1)

Publication Number Publication Date
ATE530188T1 true ATE530188T1 (de) 2011-11-15

Family

ID=39737685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08714327T ATE530188T1 (de) 2007-03-02 2008-02-29 Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs

Country Status (8)

Country Link
US (1) US8372834B2 (de)
EP (1) EP2131849B1 (de)
CN (1) CN101657203B (de)
AT (1) ATE530188T1 (de)
AU (1) AU2008222592B2 (de)
CA (1) CA2679919C (de)
ES (1) ES2373867T3 (de)
WO (1) WO2008106721A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
DE102009043717A1 (de) * 2009-10-01 2011-04-07 Westfälische-Wilhelms Universität Münster Fluorcyclodextrine
UA98665C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
UA98666C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CN104548103B (zh) * 2013-10-17 2018-04-10 江西中医药大学 氧化石墨烯和氯霉素直接结合的复合物的制备方法
WO2023010150A1 (en) * 2021-08-04 2023-02-09 Detsamma Investments Pty Ltd Methods of treating brain cancer
CN114920859B (zh) * 2022-05-11 2023-09-26 宁夏医科大学总医院 5-氟尿嘧啶-1-丁酰基-β-环糊精第二面衍生物及制备方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
IT1237509B (it) 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376658A (en) 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
EP0715854B1 (de) 1994-11-11 2003-09-10 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6025488A (en) 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU2001240001A1 (en) 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6620816B2 (en) 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
US20040033271A1 (en) 2001-12-03 2004-02-19 Seth Lederman Methods for contemporaneous administration of levamisole and 5-fluorouracil
WO2004006859A2 (en) 2002-07-16 2004-01-22 Sonus Pharmaceuticals, Inc. Platinum compound
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
DE10314377A1 (de) 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
US20040220135A1 (en) 2003-04-30 2004-11-04 Sirtex Medical Limited Combination therapy for treatment of neoplasia
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
US20070280944A1 (en) 2004-04-02 2007-12-06 Adventrx Pharmaceuticals, Inc. Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
CN100588428C (zh) 2005-08-16 2010-02-10 沈阳药科大学 氟尿嘧啶-右旋糖酐偶联物及其制备方法

Also Published As

Publication number Publication date
US20100063057A1 (en) 2010-03-11
EP2131849A1 (de) 2009-12-16
CA2679919A1 (en) 2008-09-12
CA2679919C (en) 2015-12-15
CN101657203B (zh) 2012-09-05
US8372834B2 (en) 2013-02-12
EP2131849A4 (de) 2010-03-24
CN101657203A (zh) 2010-02-24
AU2008222592A1 (en) 2008-09-12
ES2373867T3 (es) 2012-02-09
EP2131849B1 (de) 2011-10-26
AU2008222592B2 (en) 2013-09-26
WO2008106721A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
ATE530188T1 (de) Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
CY1121363T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
ATE469158T1 (de) Heteroalkylgebundene pyrimidinderivate
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201070786A1 (ru) Бензофуропиримидиноны
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
SV2010003463A (es) Compuestos organicos
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
IN2012DN01641A (de)
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
IN2012DN01642A (de)
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties